United States Patent US 8,071,623: Scope, Claims, and US Patent Landscape
US 8,071,623 is a chemical and composition patent directed to indazole-7-carboxamide derivatives with a constrained substitution pattern on the indazole ring (R1 and R2 each restricted to hydrogen or fluorine) and a benzene substituent bearing a piperidine moiety. The asserted claim set is broad at the generic level (formula claims with small substituent sets) and then narrows sharply to enumerated “selected” compounds that lock key structural variants (notably indazole carboxamide substitutions at defined positions, and (3R)/(3S) piperidine stereochemistry). Claim 9 adds formulation protection.
What does the claim scope cover in chemical terms?
Core scaffolds and permitted substitution pattern
The claims are structured around multiple “formula” definitions (Claims 1-4) with a shared constraint:
- R1 is hydrogen or fluorine
- R2 is hydrogen or fluorine
- covered are pharmaceutically acceptable salts, stereoisomers, and tautomers (with some claim-specific differences on which variants are included).
This limits the patent’s generic coverage to indazole-7-carboxamide derivatives where only two positions (corresponding to R1 and R2 in the formula) can vary, and each position has only two options (H or F). That structure-level limitation tends to increase enforceability clarity because many competitors will not land in the same two-position fluorination space.
Explicit chemical families claimed
Even without reproducing the full formula definitions (the claim text provided includes the variable definitions but not the full structural formula drawings), Claims 5-8 make the practical scope legible by listing the specific compounds.
Across the enumerated compounds, the scaffold consistently includes:
- 2H-indazole-7-carboxamide core
- substitution at the 2-position of the indazole ring with a para-substituted phenyl bearing piperidin-3-yl
- optional fluoro substitutions on the indazole ring and optionally on the phenyl ring (as reflected in the named “5-fluoro” and “3-fluoro-4-...” variants)
Stereochemical scope
The claim set does not treat stereochemistry as optional only at the generic level. It also explicitly lists stereospecific compounds:
- (3R)-piperidin-3-yl substituted phenyl variants (e.g., Claim 5 includes multiple (3R) entries)
- (3S)-piperidin-3-yl substituted phenyl variants (e.g., Claim 5 includes multiple (3S) entries)
Because piperidine at the 3-position creates a stereocenter in the named analogs, these entries materially control infringement risk. A generic “stereoisomer” inclusion can still be argued to cover a mixture, but a competitor making only one enantiomer outside the listed stereochemical entries often creates a fact-intensive infringement posture. Here, the patent itself enumerates both (3R) and (3S), strengthening coverage for either single-enantiomer manufacture.
How broad are the formula claims versus the enumerated compound claims?
Claims 1-4: generic formula coverage with limited substituent choice
From your text:
- Claim 1: “A compound of formula I” with R1 and R2 each H or F; covers pharmaceutically acceptable salts, stereoisomers, or tautomers.
- Claim 2: “A compound of claim 1 of formula II” with R1 and R2 as defined in claim 1; or salts, stereoisomers, or tautomers.
- Claim 3: “A compound of claim 1 of formula III” with R1 and R2 as defined; or salts or tautomers (no stereoisomer language appears in Claim 3 as provided).
- Claim 4: “A compound of claim 1 of formula IV” with R1 and R2 as defined; or salts or tautomers (again, no stereoisomer language appears in Claim 4 as provided).
Key practical point: even though Claims 1-4 are “formula” claims, the variable set is narrowly defined (only H or F at two positions). Enforceability in US practice often improves when the generic claim aligns with a small substitution space, because claim construction has fewer degrees of freedom.
Claims 5-8: narrow enumerated set with defined fluorination and stereochemistry
Claims 5-8 act like “coverage anchors” because they list named chemical entities. These claims are materially narrower than Claims 1-4 but are often the most litigable.
Claim 5 explicitly includes a list of compounds of the form:
- 2-(4-Piperidin-3-ylphenyl)-2H-indazole-7-carboxamide
- multiple stereospecific variants:
- “2-{4-[(3R)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide”
- “2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide”
- indazole 5-fluoro analogs, again with (3R)/(3S) variants
- further phenyl ring fluorination variants such as:
- “5-fluoro-2-(3-fluoro-4-piperidin-3-ylphenyl)-2H-indazole-7-carboxamide”
- and “5-fluoro-2-{3-fluoro-4-[(3R)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide”
- and corresponding (3S) version
- plus pharmaceutically acceptable salts, tautomers or stereoisomers of those.
Claim 6 narrows Claim 5 to two specific stereochemical entries:
- the (3R) and (3S) “2-{4-[(3R)/(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide” pair
- plus salts or tautomers.
Claim 7 is a single compound:
- “2-(4-Piperidin-3-ylphenyl)-2H-indazole-7-carboxamide”
- plus salts or tautomers.
Claim 8 is a single stereospecific compound:
- “2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide”
- plus salts or tautomers.
Net effect: the enumerated set gives the patent two layers:
1) a generic “substituent-limited” scaffold definition (Claims 1-4), and
2) a specific list of competitor-realistic analogs including stereochemistry and fluorination positions (Claims 5-8).
What is the formulation scope?
Claim 9:
- “A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof in association with a pharmaceutically acceptable carrier.”
This is a standard chemical composition claim. The practical reach depends on what is treated as the “compound of claim 1.” Given Claims 1-4 set a small substitution space (R1/R2 each H or F) and include stereoisomers/salts/tautomers, Claim 9 can cover:
- compositions of generic-covered compounds,
- including specific stereochemical and tautomeric forms,
- formulated with typical carriers used in oral, topical, or injectable dosage forms (the carrier type is not restricted in the claim text you provided).
How does US 8,071,623 likely sit inside the broader US patent landscape?
A complete US “landscape” requires prosecution history, family members, and the surrounding patent set that share the same chemical series and indication. Those details are not present in the claim text you provided. Under the constraints here, the only defensible landscape conclusions are structural and claim-based:
1) Likely positioning versus close analog patents
Because Claims 1-4 are limited to fluorine substitution at two indazole positions (R1/R2 each H or F), the patent’s generic reach will overlap most strongly with:
- patents covering the same 2H-indazole-7-carboxamide scaffold and the same 2-aryl substitution with a piperidin-3-yl group,
- patents that vary only H/F status at the two corresponding indazole positions,
- patents that include stereochemically resolved piperidine variants.
Conversely, patents that:
- replace the carboxamide at position 7 with another functional group,
- remove or fundamentally alter the piperidin-3-yl motif or its attachment pattern,
- introduce fluorine (or another substituent) beyond the two positions mapped to R1 and R2,
tend to fall outside the claim’s generic boundary and would likely need to be evaluated via the enumerated compound list (Claims 5-8) or via doctrine of equivalents.
2) Likely positioning versus “next-generation” fluorinated analogs
Claims 5 and the listed entries include:
- “5-fluoro” indazole variants, and
- a “3-fluoro-4-...” phenyl substitution pattern paired to the piperidin-3-yl group.
So, the patent already reaches some higher-fluoro substitution patterns, at least in the particular enumerated arrangements. Competitors seeking to design around would typically look for:
- non-listed phenyl fluorination patterns,
- fluorine placement not captured by the named “5-fluoro” and “3-fluoro-4-...” structures,
- removal of stereochemical specificity (or a deliberate change to a different stereocenter not covered by the enumerated (3R)/(3S) examples).
3) Likely positioning versus salt/form patenting
Claim 1 includes “pharmaceutically acceptable salts, stereoisomers, or tautomers.” Claim 9 includes salts/tautomers/stereoisomers. This means the patent is already designed to block common downstream salt-form strategies unless a later patent:
- claims a materially different chemical entity (not a salt/tautomer/stereoisomer), or
- claims a different composition not read on “in association with a pharmaceutically acceptable carrier” (rare for generic drug products, unless there is a specific non-standard limitation).
Claim-by-claim scope map (what you can enforce and what can be designed around)
| Claim |
Scope type |
What it covers (from provided text) |
Main design-around lever |
| 1 |
Generic formula |
Formula I with R1, R2 ∈ {H, F}; covers salts, stereoisomers, tautomers |
Change scaffold so it is not formula I; change either substitution position mapping beyond R1/R2; remove/alter core not read as formula I |
| 2 |
Generic formula dependent |
Formula II with same R1/R2 limits; includes salts, stereoisomers, tautomers |
Same as above; also avoid mapping into formula II definition |
| 3 |
Generic formula dependent |
Formula III with R1/R2 limits; covers salts or tautomers (no stereoisomer language as provided) |
If relevant, argue that stereoisomers are not encompassed for that formula-specific claim as drafted |
| 4 |
Generic formula dependent |
Formula IV with R1/R2 limits; covers salts or tautomers |
Same as Claim 3 |
| 5 |
Enumerated list |
Named compounds covering specific indazole substitution (including “5-fluoro”) and phenyl/piperidine arrangements, plus salts, tautomers or stereoisomers |
Avoid all listed entries; and attempt to stay outside formula I/II if possible |
| 6 |
Narrow enumerated |
Two (3R)/(3S) piperidine stereochemical entries; plus salts/tautomers |
Use a different stereochemical set or non-covered stereochemistry only if not already covered by Claim 5 |
| 7 |
Single enumerated |
Unstereospecified “2-(4-Piperidin-3-ylphenyl)-2H-indazole-7-carboxamide” plus salts/tautomers |
Use a specific enantiomer not encompassed by this claim’s interpretation, or move to a different substitution pattern not covered |
| 8 |
Single enumerated |
The (3S) piperidine stereochemical entry plus salts/tautomers |
Manufacture only (3R) or a different configuration not covered by Claim 8, subject to Claim 5 coverage |
| 9 |
Composition |
Dosage composition with compound of claim 1 (or salt/tautomer/stereoisomer) + pharmaceutically acceptable carrier |
Use a different active ingredient not falling within claim 1 compounds; standard carrier choice rarely provides a carve-out |
What is the actionable freedom-to-operate posture implied by the claims?
Based strictly on the provided claims text:
1) Active ingredient overlap risk is high for competitors whose lead candidates fall into the indazole-7-carboxamide + 2-(piperidin-3-ylphenyl) family with H/F status at the two R1/R2 positions, because Claims 1-4 capture that substitution-limited design space.
2) Stereochemistry is not a clean escape hatch because Claim 5 lists both (3R) and (3S) variants, and Claims 6 and 8 reinforce stereochemical coverage at the “selected compound” level.
3) Formulation barriers are broad because Claim 9 reads on compositions of any claim-1 compound with a pharmaceutically acceptable carrier, which is the standard formulation umbrella.
Key Takeaways
- The patent’s generic coverage is constrained to R1 and R2 each being H or F, limiting the indazole fluorination patterns covered by the formula claims.
- Claims 5-8 provide enumerated, stereospecific anchors, including both (3R) and (3S) piperidin-3-yl variants and multiple fluoro substitution patterns (including “5-fluoro” and a “3-fluoro-4-...” phenyl pattern).
- Claim 9 extends protection to pharmaceutical compositions of any claim-1 compound (including salts/tautomers/stereoisomers) with a pharmaceutically acceptable carrier.
- Design-around work should focus on leaving the formula boundaries and evading all enumerated structures, not on minor formulation changes.
FAQs
1) Does US 8,071,623 cover both enantiomers of the piperidine stereocenter?
Yes. The enumerated list in Claim 5 includes compounds with (3R) and (3S) piperidin-3-yl substitution, and Claims 6 and 8 separately list (3R)/(3S) entries in the “selected” subset.
2) Are fluorination options limited to hydrogen or fluorine?
Yes for the formula claims: R1 and R2 are each hydrogen or fluorine in Claims 1-4 as provided.
3) Is the patent limited to a specific dosage form?
No. Claim 9 covers a pharmaceutical composition with the active ingredient (from Claim 1) and “a pharmaceutically acceptable carrier,” without restricting dosage form.
4) Can competitors rely on salts or tautomers to avoid the generic coverage?
No, because the claims explicitly include pharmaceutically acceptable salts and tautomers in the scope of the covered compounds (and Claim 9 repeats those inclusions).
5) Which claims are most useful for infringement arguments against specific analogs?
The enumerated selected-compound claims (Claims 5-8) are typically the most direct for mapping a concrete competitor structure to a named claim, while Claims 1-4 are the fallback for coverage of unenumerated members within the defined formula space.
References
[1] U.S. Patent 8,071,623, “Method and compositions,” claims as provided by user.
